Determining the Effect of Six Weeks of Cannabis Abstinence on Fronto- Striatal fMRI Markers in Adolescents With Cannabis Use Disorder (ABSCAN)
- Conditions
- Cannabis Use Disorder
- Registration Number
- NCT06124846
- Lead Sponsor
- University of Minnesota
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria:<br><br> - Male and female adolescents between the ages of 15 and 18 (inclusive).<br><br> - Have a parent or legal guardian who is able and willing to provide written informed<br> consent.<br><br> - Competent and willing to provide written informed assent (participants <18) or<br> consent (participants=18).<br><br> - Native English speaker.<br><br> - Have a parent or legal guardian who is fluent in English.<br><br> - Able to commit to 8 study visits in approximately 60 days (6 weeks).<br><br> - Able to safely participate in the protocol and appropriate for outpatient level of<br> care, in the opinion of the PI.<br><br> - No active psychosis or current use of antipsychotic medications.<br><br> - Participants taking psychotropic medications will be included if the medications<br> have been stable for 6 weeks and are expected to remain stable for the duration of<br> their study participation (i.e., through the third MRI).<br><br> - For CB-Abst (n=24) and CB-Mon (n=20) groups: at least 5 days of use per week on<br> average in the past two months and meet DSM-V cannabis use disorder (CUD; at least<br> Mild) criteria. Cannabis use reported within seven days of baseline visit. Positive<br> qualitative urine toxicology test at baseline for THC. No immediate plan to<br> discontinue cannabis use.<br><br> - For Con (n=20): no lifetime history of cannabis use. Negative qualitative urine<br> toxicology test at baseline for THC. No immediate plans to begin cannabis use.<br><br>Exclusion Criteria:<br><br> - Past twelve-month history of substance use disorders (except for Cannabis Use<br> Disorder in CB-Abst and CB-Mon), assessed via semi-structured psychodiagnostics<br> interview at baseline.<br><br> - Current daily nicotine use (e.g., via electronic and/or combustible cigarettes).<br><br> - Contraindications for MRI (ascertained via participant and parent report), including<br> but not limited to:<br><br> 1. Metal implants such as surgical clips or pacemakers, or history of working with<br> metal, unless the possibility of a metal fragment can be ruled out by recent<br> orbital scans.<br><br> 2. Prior head trauma with neurological sequelae.<br><br> 3. Claustrophobia.<br><br> 4. Weight incompatible with MRI safety.<br><br> 5. Pregnancy.<br><br> - Previous or current diagnosis of psychosis, cognitive disability, or bipolar<br> disorder.<br><br> - Active suicidality.<br><br> - Taking a psychotropic medication that has not reached stability criterion (same<br> medication type and dose for 6 weeks with no planned changes over the study period).<br><br> - Any other medical or psychiatric condition deemed serious or contraindicated for any<br> study procedures by Dr. Tervo-Clemmens.
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Brain activation during Monetary Incentive Delay Task (reward processing);Brain connectivity during resting-state functional neuroimaging protocol
- Secondary Outcome Measures
Name Time Method Self-reported Impulsivity via UPPS-P scale